Simons, F.Estelle R.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
F. Estelle R. Simons Canadian physician and researcher
Simons, F. E. R.
Simons, F. E. R., 1945-
VIAF ID: 238873883 (Personal)
Permalink: http://viaf.org/viaf/238873883
Preferred Forms
-
100 0 _
‡a
F. Estelle R. Simons
‡c
Canadian physician and researcher
-
200 _ |
‡a
Simons
‡b
F. Estelle R.
-
100 1 _ ‡a Simons, F. E. R
-
100 1 0
‡a
Simons, F. E. R.
-
100 1 _
‡a
Simons, F. E. R.
-
100 1 _ ‡a Simons, F. E. R. ‡d (1945- )
-
100 1 _ ‡a Simons, F. E. R. ‡d (1945- ).
-
100 1 _ ‡a Simons, F. E. R., ‡d 1945-
-
100 1 _
‡a
Simons, F. Estelle R.
-
100 1 _ ‡a Simons, F. Estelle R.
-
100 1 _
‡a
Simons, F. Estelle R.
-
100 1 _ ‡a Simons, F.Estelle R.
4xx's: Alternate Name Forms (7)
Works
| Title | Sources |
|---|---|
| Ancestors of allergy |
|
| Clinical Importance of Inhibition of Mediator Relase by Antihistamines : Washington, DC, January 18, 1992 |
|
| Eventual full-text publication of research abstracts presented at an allergy/immunology meeting |
|
| Experimental studies about the origin of the "wedge-blood" in partially atelectatic lungs of mongrel dogs (author's transl) |
|
| Fatal anaphylaxis registries data support changes in the who anaphylaxis mortality coding rules |
|
| Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis |
|
| H1-antihistamines and the central nervous system. |
|
| H1-antihistamines for primary mast cell activation syndromes: a systematic review |
|
| H1-antihistaminic activity of cetirizine and fexofenadine in allergic children |
|
| H2-antihistamines for the treatment of anaphylaxis with and without shock: a systematic review |
|
| Histamine and H1-antihistamines: Celebrating a century of progress |
|
| Histamine and H1-receptor antagonists in allergic disease |
|
| Histamine receptors are hot in immunopharmacology |
|
| History of the World Allergy Organization: The World Allergy Organization Congress - XVIII ICACI, Vancouver 2003. |
|
| How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. |
|
| Human metapneumovirus elicits weak IFN-gamma memory responses compared with respiratory syncytial virus |
|
| Human subjects without peanut allergy demonstrate T cell-dependent, TH2-biased, peanut-specific cytokine and chemokine responses independent of TH1 expression |
|
| Hydroxyzine- and cetirizine-loaded liposomes: effect of duration of thin film hydration, freeze-thawing, and changing buffer pH on encapsulation and stability |
|
| Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model |
|
| IgE antibody responses in young children with atopic dermatitis |
|
| IgE modulates neutrophil survival in asthma: role of mitochondrial pathway |
|
| Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites |
|
| Inhaled corticosteroids in childhood asthma: Income differences in use. |
|
| Insights and advances in chronic urticaria: a Canadian perspective |
|
| International consensus on (ICON) anaphylaxis |
|
| Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study |
|
| Lack of worldwide availability of epinephrine autoinjectors for outpatients at risk of anaphylaxis |
|
| Locomotor activity and anorexogenic action |
|
| Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis. |
|
| MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. |
|
| Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria |
|
| Mosquito allergy: immune mechanisms and recombinant salivary allergens |
|
| Mosquito saliva-specific IgE and IgG antibodies in 1059 blood donors |
|
| Mosquito salivary allergen Aed a 3: cloning, comprehensive molecular analysis, and clinical evaluation |
|
| Moving forward in pediatric allergy & immunology |
|
| New criteria for classification of H1 blockers |
|
| New visions for anaphylaxis: an iPAC summary and future trends |
|
| Novel Recombinant Interleukin-13 Peptide-based Vaccine Reduces Airway Allergic Inflammatory Responses in Mice |
|
| Oral immunotherapy for peanut allergy |
|
| Peanut allergy: recent advances |
|
| Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened? |
|
| Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis |
|
| Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective |
|
| Practical guide to skin prick tests in allergy to aeroallergens. |
|
| Prospective evaluation of an anaphylaxis education mini-handout: the AAAAI Anaphylaxis Wallet Card |
|
| Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community |
|
| rAed a 4: A New 67-kDa Aedes aegypti Mosquito Salivary Allergen for the Diagnosis of Mosquito Allergy. |
|
| Rapidly-disintegrating sublingual tablets of epinephrine: role of non-medicinal ingredients in formulation development |
|
| Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma |
|
| Regulation of the high affinity IgE receptor (Fc epsilonRI) in human neutrophils: role of seasonal allergen exposure and Th-2 cytokines |
|
| Relevance of H1-receptor occupancy to H1-antihistamine dosing in children |
|
| Reovirus serotypes elicit distinctive patterns of recall immunity in humans |
|
| Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). |
|
| Risk assessment in anaphylaxis: current and future approaches |
|
| Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper |
|
| Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study |
|
| Safety of levocetirizine treatment in young atopic children: An 18-month study |
|
| Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) |
|
| Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. |
|
| Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper |
|
| Simultaneous analysis of the H1-antihistamine acrivastine and the decongestant pseudoephedrine hydrochloride by high-performance liquid chromatography |
|
| Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile |
|
| Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis |
|
| Sustained release theophylline in the treatment of chronic reversible airways obstruction, 1984: |
|
| Systemic chemokine and chemokine receptor responses are divergent in allergic versus non-allergic humans |
|
| Timing the transfer of responsibilities for anaphylaxis recognition and use of an epinephrine auto-injector from adults to children and teenagers: pediatric allergists' perspective |
|
| Update on rupatadine in the management of allergic disorders |
|
| Uptake of EpiPen and Allerject (Auvi-Q) epinephrine auto-injectors in Manitoba children |
|
| Voluntarily reported unintentional injections from epinephrine auto-injectors |
|
| Work productivity in rhinitis using cell phones: The MASK pilot study |
|
| World allergy organization guidelines for the assessment and management of anaphylaxis |
|
| World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) |
|
| Zastosowanie adrenaliny do samodzielnego wstrzyknięcia w leczeniu anafilaksji |
|
| Zinc finger-like structure in U1-specific protein C is essential for specific binding to U1 snRNP |
|
